Literature DB >> 2610717

Pharmacokinetics of acarbose. Part I: Absorption, concentration in plasma, metabolism and excretion after single administration of [14C]acarbose to rats, dogs and man.

H J Ahr1, M Boberg, H P Krause, W Maul, F O Müller, H J Ploschke, H Weber, C Wünsche.   

Abstract

The absorption, disposition, metabolism, and excretion of acarbose (O-4,6-dideoxy-4-[[(1S, 4R, 5S, 6S)-4,5,6-trihydroxy-3- (hydroxymethyl)-2- cyclohexen-1-yl]amino]-a-D-glucopyranosyl- (1----4)-O-a-D-glucopyranosyl- (1----4) -D-glucopyranose, Bay g 5421) have been studied following a single administration of the 14C-labelled compound to rats and dogs via different routes (intravenous, oral, intraduodenal) in the dose range of 2-200 mg.kg-1 as well as to man in a single oral dose of 200 mg. After intravenous administration [14C]acarbose was eliminated rapidly and completely via the renal route. There was no indication for a systemic metabolization of [14C]acarbose. The (renal) clearance for [14C]acarbose was in the range of the glomerular filtration rate. After oral administration [14C]acarbose was very poorly absorbed (1-2% of dose in rats and man and 4% in dogs). Additionally, up to 35% of the radioactivity of [14C]acarbose were absorbed after degradation by digestive enzymes and/or intestinal microorganisms. The delayed and biphasic absorption of the radioactivity strongly influenced the plasma concentration vs time profiles of total radioactivity. Maximum concentrations dependent on the degree of microbial degradation (dog less than rat, man) and on the intestinal transit time were reached at 1.2 h (dogs), 8 h (rats) and 14-24 h (man). The excretion of the radioactivity absorbed occurred rapidly and completely mostly via the renal route.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2610717

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  13 in total

1.  Lack of interaction between thioctic acid, glibenclamide and acarbose.

Authors:  C H Gleiter; K H Schreeb; S Freudenthaler; M Thomas; M Elze; H Fieger-Büschges; H Potthast; E Schneider; B S Schug; H H Blume; R Hermann
Journal:  Br J Clin Pharmacol       Date:  1999-12       Impact factor: 4.335

Review 2.  Pharmacokinetic-pharmacodynamic relationships of Acarbose.

Authors:  T Salvatore; D Giugliano
Journal:  Clin Pharmacokinet       Date:  1996-02       Impact factor: 6.447

3.  Acarbose is an effective adjunct to dietary therapy in the treatment of hypertriglyceridaemias.

Authors:  M Malaguarnera; I Giugno; P Ruello; M Rizzo; M Motta; G Mazzoleni
Journal:  Br J Clin Pharmacol       Date:  1999-10       Impact factor: 4.335

Review 4.  Diabetes therapies in hemodialysis patients: Dipeptidase-4 inhibitors.

Authors:  Yuya Nakamura; Hitomi Hasegawa; Mayumi Tsuji; Yuko Udaka; Masatomo Mihara; Tatsuo Shimizu; Michiyasu Inoue; Yoshikazu Goto; Hiromichi Gotoh; Masahiro Inagaki; Katsuji Oguchi
Journal:  World J Diabetes       Date:  2015-06-25

Review 5.  The Effectiveness of Antidiabetic Drugs in Treating Dementia: A Peek into Pharmacological and Pharmacokinetic Properties.

Authors:  Jiro Ogura; Hiroaki Yamaguchi
Journal:  Int J Mol Sci       Date:  2022-06-11       Impact factor: 6.208

6.  The human microbiome encodes resistance to the antidiabetic drug acarbose.

Authors:  Jared Balaich; Michael Estrella; Guojun Wu; Philip D Jeffrey; Abhishek Biswas; Liping Zhao; Alexei Korennykh; Mohamed S Donia
Journal:  Nature       Date:  2021-11-24       Impact factor: 69.504

7.  High-throughput screening of FDA-approved drugs using oxygen biosensor plates reveals secondary mitofunctional effects.

Authors:  Sunil Sahdeo; Alexey Tomilov; Kelly Komachi; Christine Iwahashi; Sandipan Datta; Owen Hughes; Paul Hagerman; Gino Cortopassi
Journal:  Mitochondrion       Date:  2014-07-14       Impact factor: 4.160

8.  Diabetes medications as potential calorie restriction mimetics-a focus on the alpha-glucosidase inhibitor acarbose.

Authors:  Daniel L Smith; Rachael M Orlandella; David B Allison; Lyse A Norian
Journal:  Geroscience       Date:  2020-10-02       Impact factor: 7.713

9.  Improving acarbose production and eliminating the by-product component C with an efficient genetic manipulation system of Actinoplanes sp. SE50/110.

Authors:  Qinqin Zhao; Huixin Xie; Yao Peng; Xinran Wang; Linquan Bai
Journal:  Synth Syst Biotechnol       Date:  2017-11-27

10.  Evaluation of the pharmacokinetics of metformin and acarbose in the common marmoset.

Authors:  Elizabeth Fernandez; Corinna Ross; Hanyu Liang; Martin Javors; Suzette Tardif; Adam B Salmon
Journal:  Pathobiol Aging Age Relat Dis       Date:  2019-08-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.